Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | IDEA-FRANCE: ctDNA as a predictive value for adjuvant treatment duration

Thierry André • 29 Sep 2019
ESMO 2019
Colorectal Cancer Gastrointestinal Cancer
IDEA-FRANCE

Thierry André, MD, Saint-Antoine Hospital, Paris, France, talks about the IDEA-FRANCE Phase III study (NCT00958737) of ctDNA as a prognostic and predictive value for adjuvant treatment duration. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Thierry André

1:38
Immuno-oncology in MSI colorectal cancer
Thierry André • 20 Jan 2021
2:11
Pembrolizumab vs. chemo in first-line mCRC
Thierry André • 18 Jan 2021
3:53
GARNET: dostarlimab, a PD-1 antibody in advanced solid tumors
Thierry André • 18 Jan 2021
2:20
AVANT: bevacizumab + oxaliplatin-based chemo for colon cancer
Thierry André • 29 Sep 2019

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals